2,856 reports of this reaction
2.3% of all FLUOROURACIL reports
#10 most reported adverse reaction
THROMBOCYTOPENIA is the #10 most commonly reported adverse reaction for FLUOROURACIL, manufactured by Bausch Health US, LLC. There are 2,856 FDA adverse event reports linking FLUOROURACIL to THROMBOCYTOPENIA. This represents approximately 2.3% of all 124,552 adverse event reports for this drug.
Patients taking FLUOROURACIL who experience thrombocytopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THROMBOCYTOPENIA is a less commonly reported adverse event for FLUOROURACIL, but still significant enough to appear in the safety profile.
In addition to thrombocytopenia, the following adverse reactions have been reported for FLUOROURACIL:
The following drugs have also been linked to thrombocytopenia in FDA adverse event reports:
THROMBOCYTOPENIA has been reported as an adverse event in 2,856 FDA reports for FLUOROURACIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
THROMBOCYTOPENIA accounts for approximately 2.3% of all adverse event reports for FLUOROURACIL, making it a notable side effect.
If you experience thrombocytopenia while taking FLUOROURACIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.